Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is trading at neutral levels on P/FCF.
Buy
Sell